Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
98.6M
-
Number of holders
-
150
-
Total 13F shares, excl. options
-
63.8M
-
Shares change
-
+1.34M
-
Total reported value, excl. options
-
$926M
-
Value change
-
+$31M
-
Put/Call ratio
-
0.68
-
Number of buys
-
102
-
Number of sells
-
-35
-
Price
-
$14.50
Significant Holders of ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) as of Q3 2024
173 filings reported holding SPRY - ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share as of Q3 2024.
ARS Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (SPRY) has 150 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 63.8M shares
of 98.6M outstanding shares and own 64.69% of the company stock.
Largest 10 shareholders include DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (11.1M shares), RA CAPITAL MANAGEMENT, L.P. (10.9M shares), ORBIMED ADVISORS LLC (8.29M shares), BlackRock, Inc. (4.25M shares), SR One Capital Management, LP (4.01M shares), VANGUARD GROUP INC (3.35M shares), FRANKLIN RESOURCES INC (2.84M shares), STATE STREET CORP (2.05M shares), GEODE CAPITAL MANAGEMENT, LLC (1.23M shares), and Nextech Invest Ltd. (1.11M shares).
This table shows the top 150 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.